Celltrion Showcases Omlyclo at 2026 European Respiratory Society Congress

Celltrion said on Sept. 10 that it participated in the 2026 European Respiratory Society (ERS) Congress, held in Barcelona, Spain, from Sept. 5 to 9, where it showcased Omlyclo, a treatment for chronic urticaria and allergic asthma.
Omlyclo, presented at the respiratory congress, contains omalizumab. Omalizumab is an antibody therapy used to treat allergic diseases.
Celltrion launched Omlyclo in Europe late last year and added a 300 mg formulation in August this year. The company offers various dosages and devices to provide more options for healthcare professionals. It also highlighted storage stability and convenience, a latex-free product configuration and reliable supply capabilities as competitive advantages.
Omlyclo is currently sold in 26 European countries. Celltrion estimates that its market share in Spain exceeded 90% as of July this year. The company plans to expand sales across Europe.
Celltrion will also participate in Global Urticaria Forum 2026 in Berlin, Germany, in December as it continues efforts to expand sales of Omlyclo.
